Classen Annika Yanina, Sandherr Michael, Vehreschild Jörg Janne, von Lilienfeld-Toal Marie
Medizinische Fakultät und Uniklinik Köln, Klinik I für Innere Medizin, Universität zu Köln, Kerpener Straße 62, 50937 Köln, Deutschland.
Deutsches Zentrum für Infektionsforschung, Standort Bonn-Köln, Köln, Deutschland.
Onkologe (Berl). 2022;28(4):349-360. doi: 10.1007/s00761-022-01120-z. Epub 2022 Mar 15.
Patients with cancer are at increased risk of infection due to disease-associated or therapy-induced immunosuppression. Taking into account globally increasing antimicrobial resistance rates and negative effects associated with antibiotic treatments, the effective, appropriate and guideline-conform use of anti-infectives must be promoted in this clinical setting. The application of antibacterial prophylaxis should be limited to high-risk patients. Infection diagnostics and therapeutic strategies differ depending on the extent of expected immunosuppression and the patient's individual risk factors.
癌症患者由于疾病相关或治疗引起的免疫抑制,感染风险增加。考虑到全球抗菌药物耐药率不断上升以及抗生素治疗的负面影响,在这种临床环境中必须促进抗感染药物的有效、合理和符合指南的使用。抗菌预防的应用应仅限于高危患者。感染诊断和治疗策略因预期免疫抑制的程度和患者的个体风险因素而异。